Attached files
file | filename |
---|---|
8-K - CURRENT REPORT - PALATIN TECHNOLOGIES INC | ptn_8k.htm |
EXHIBIT
99.1
Palatin Technologies Announces
Appointment of Anthony M. Manning, Ph.D. to
Board of Directors
CRANBURY,
N.J., September 12, 2017 -- Palatin Technologies, Inc. (NYSE MKT:
PTN), a biopharmaceutical company developing targeted,
receptor-specific peptide therapeutics for the treatment of
diseases with significant unmet medical need and commercial
potential, announced today that Anthony M. Manning, Ph.D. was
appointed to Palatin’s Board of Directors on September 7,
2017. Dr. Manning currently serves as the Senior Vice President of
Research at Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA),
Cambridge, MA.
"We are
pleased to welcome Anthony to our Board," said John Prendergast,
Ph.D., Chairman of the Board of Palatin Technologies. "Anthony is
an accomplished pharmaceutical executive with extensive experience
translating research into innovative products. Earlier this year we
licensed bremelanotide, our Phase 3 treatment for female sexual
dysfunction, to AMAG Pharmaceuticals. As we now begin to focus on
the development of our earlier stage assets, Anthony will provide
valuable insights and perspective with respect to our research,
development and business strategy."
Dr.
Manning, age 55, is responsible for research and the discovery of
novel products as the Senior Vice President of Research at Momenta
Pharmaceuticals, Inc. Since joining Momenta, his team has advanced
three novel autoimmune drugs into development. Prior to Momenta,
Dr. Manning was Vice President and Head of Immunology Research for
Biogen Idec, Inc. Before that, he was Vice President and Global
Head of Inflammation, Autoimmunity and Transplantation Research at
Roche Pharmaceuticals.
Anthony
M. Manning holds a Ph.D. from the University of Otago, New Zealand,
and has authored more than 100 peer-reviewed publications and
patents in the fields of signal transduction, autoimmune diseases
and drug discovery.
Davis
Board Consultants of Boston, MA assisted in the
search.
About Palatin Technologies, Inc.
Palatin
Technologies, Inc. is a biopharmaceutical company developing
targeted, receptor-specific peptide therapeutics for the treatment
of diseases with significant unmet medical need and commercial
potential. Palatin’s strategy is to develop products and then
form marketing collaborations with industry leaders in order to
maximize their commercial potential. For additional information,
please visit http://www.palatin.com.
Palatin
Technologies Investor Inquiries:
Stephen
T. Wills, CPA, MST
Chief
Operating Officer/Chief Financial Officer
Tel:
(609) 495-2200/info@palatin.com
Palatin
Technologies Media Inquiries:
Paul
Arndt, MBA, LifeSci Advisors, LLC
Managing
Director
Tel:
(646) 597-6992 / Paul@LifeSciAdvisors.com
###